Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: A sodium-glucose cotransporter-2 inhibitor (SGLT2i) improves clinical outcomes in patients with type 2 diabetes (T2DM) and cardiovascular disease. Also use of SGLT2i was associated with a reduction of atrial fibrillation (AF) burde...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Y, Seung, J H, Park, S Y, Kim, S H, Kim, H J, H, Y M, Kim, J H, Kim, T S, Jang, S W, Oh, Y S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
10.2.3 - Heart Failure in Atrial Fibrillation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206983/
http://dx.doi.org/10.1093/europace/euad122.048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206983/
http://dx.doi.org/10.1093/europace/euad122.048

Ejemplares similares